Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 7, Issue 6, Pages 815-822Publisher
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.7.815
Keywords
androgen receptor; prostate cancer; splicing variants; alternative splicing
Categories
Funding
- NIH [CA106504]
- DOD [W81XWH-08-1-0174]
- NATIONAL CANCER INSTITUTE [R01CA106504] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Prostate cancer is the second leading cause of cancer-related death in American men. Although most prostate cancers are initially androgen-dependent and respond to androgen ablation therapy, majority of them eventually relapse and progress into incurable castration-resistant (or hormone refractory) prostate cancer. The underlying mechanisms are the focus of intensive investigation for development of more effective treatment. Mounting evidence from both clinical and basic research has demonstrated that the activity of the androgen receptor (AR) is still required for castration-resistant prostate cancer. Multiple mechanisms by which AR is re-activated under androgen-depleted conditions may be involved in the development of castration resistance. The recent identification of AR splicing variants may add another layer of complexity in AR biology. The present review summarizes recent progress in study of AR splicing variants in prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available